NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

Another reason that evidence of some immune response to the tumor, prior to DCVax-L administration, might be predictive of benefit from DCVax-L could be that a primed immune system would have a much stronger initial response to DCVax-L administration. The number of T-Cells for the appropriate mutant antigens would be much higher than for a patient that had not yet detected the tumor (or had a damaged immune system). Giving DCVax-L to such a patient would be like giving a second shot in a more common vaccine, such as in a hepatitis B vaccine series. The immune bloom would potentially be very dramatic. Maybe that is necessary for success of DCVax-L in spite of the very wide, mass-parallel response.